Academics

Bio

Dr. Shvetank Bhatt is an accomplished Associate Professor in the School of Health Sciences and Technology at Dr. Vishwanath Karad MIT World Peace University, located in Pune, Maharashtra, India. He holds an M. Pharm degree in Pharmacology from Manipal College of Pharmaceutical Sciences, MAHE, Manipal, Karnataka, and a Ph.D. in Neuropharmacology from Birla Institute of Technology & Science (BITS) Pilani, Pilani Campus, Rajasthan. With over 16 years of industrial and academic research experience, Dr. Bhatt specializes in CNS disorders, pain, inflammation, and immuno-oncology. He has received numerous accolades, including the Prof. Duggirala Visweswaram & Prof. Sreemantalu Satyanarayana Award for Best Paper in Pharmacology-IJPER in 2012 and 2014. Dr. Bhatt has published over 85 papers in various national and international journals and has a total citation count of 850, an h-index of 15, and an i-index of 24. His cumulative Impact Factor, according to SCOPUS, is around 200. Dr. Bhatt is a life member of the Association of Pharmaceutical Teachers of India (APTI) and the Indian Pharmacological Society (IPS).

Research Areas

Neuropharmacology and Metabolic Disorders

Publications

"1. Bhatt S, Devadoss T, Jha NK, Baidya M, Gupta G, Chellappan DK, Singh SK, Dua K. Targeting inflammation: a potential approach for the treatment of depression. Metab Brain Dis. 2023; 38(1):45-59. (Springer) (IF: 3.655)

2. Bhatt S, Kanoujia J, Mohana Lakshmi S, Patil CR, Gupta G, Chellappan DK, Dua K. Role of Brain-Gut-Microbiota Axis in Depression: Emerging Therapeutic Avenues. CNS Neurol Disord Drug Targets. 2023; 22(2):276-288. (Bentham Science) (IF 4.388)

3. Mukherjee D, Bhatt S. Biocomposite-based nanostructured delivery systems for treatment and control of inflammatory lung diseases. Nanomedicine (Lond). 2022; 17(12):845-863.(IF 6.096)

4. Bhatt S, Behl T, Sehgal A, Singh S, Sharma N, Chigurupati S, Ahmed AS, Gari SBV. Investigation of Cochlospermum religiosum leaves for antidepressant and anxiolytic activities and its synergistic effect with imipramine and fluoxetine. Environmental Science and Pollution Research 2022 Apr;29(18):27172-27181.. (Springer) (IF: 5.190).

5. Bhatt S, Nagappa AN, Patil CR. Role of oxidative stress in depression. Drug Discov Today. 2020, 25:1270-1276. (ELSEVIER) (IF-7.851)

6. Jindal A, Mahesh R, Bhatt S. Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic-pituitary-adrenal axis, cAMP signaling aspects and antioxidant defense system. Pharmacol Biochem Behav, 2015; 132, 20-32. (Elsevier) (IF-3.533)"

Google Scholar link :https://scholar.google.co.in/citations?user=sWVSgIwAAAAJ&hl=en

Scopus link :https://www.scopus.com/authid/detail.uri?authorId=57197493015

ORCID link :https://orcid.org/0000-0001-8696-3462

Research Grants :

Neuro-pharmacological Investigation of Novel Quinoxaline Carboxamides: Novel Serotonergic Modulators for their Anti-depressant and Anxiolytic Activity (UGC, Minor Research Project, 2 Lakhs Rupees, Approved in March 2013)